en · de · es · fr · pt
analytical-notes.peptides3626.com › Guide › Identity And Reported Background — Quick Reference

Identity And Reported Background — Quick Reference

By Editorial Desk · published 2026-04-30 · last reviewed 2026-06-15 · Guide

Everything below concerns TB-500. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Updated 2026-06-15. Numbers and descriptions here follow the published literature rather than marketing material.

Identity and Reported Background

TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.

Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.

Thymosin Beta-4 Fragment Background

TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.

Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.

Tb-500 at a glance

PropertyValueNotes
Reported sequenceAc-LKKTETQDescribed in most listings as the actin-binding region of thymosin beta-4
Reported molecular weightApproximately 889 DaValue shifts with the stated sequence; compare against the certificate of analysis
Parent protein length43 amino acidsThymosin beta-4; the fragment covers only a small part of it
Common synonymsTB4 fragment; thymosin beta-4 fragmentTrade-style names rather than formal nomenclature
Formal monographsNot establishedLabeling conventions differ by supplier and region

TB-500 Identity and Molecular Background

TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.

Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.

Related pages on this site

Handling Storage And Analysis

The seven-residue chain carries several polar and charged side chains, so it dissolves readily in water and in aqueous buffers near neutral pH. No cysteine is present, so disulphide formation is not a concern and reducing agents are unnecessary. Dilute ammonium hydroxide or acetonitrile-water mixtures are sometimes used for stock solutions when initial dissolution is slow. Strongly alkaline conditions and prolonged contact with oxidising agents are avoided because they can modify lysine-containing stretches, and haze in solution usually signals incomplete dissolution or aggregated material.

Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.

Reference notes

=== 13 July === DeepStateMap.Live reported that Russia had recaptured the village of Urozhaine, Donetsk Oblast. Russia formally announced its seizure of the village on 14 July, while the Ukrainian military confirmed their withdrawal from the village on 18 July. The head of the State Emergency Service in Kharkiv Oblast, Artem Kostyria, was killed along with a police officer in a double-tap Russian missile strike in Budy. Two people were killed in a separate attack near Kherson. In Russia, the governor of Rostov Oblast claimed that an oil depot was set on fire by a drone strike in Tsimlyansky District. Czech President Petr Pavel announced that Ukraine would receive 50,000 shells from July to August, with an additional 80,000-100,000 shells expected from September until the end of December.

Therefore, the Royal College of Pathologists and Royal College of Physicians have developed combined infection training, that medical trainees gain a much more patient focused experience, and undertake physician examinations in addition to pathology training. The result of this is that several regional medical deaneries no longer permit medical doctors to train in microbiology or virology as single disciplines, and instead advocate dual-specialisation as infectious disease/microbiology or infectious disease/virology. Simultaneously, the expansion of higher specialist scientist trainees in microbiology means that many of the laboratory and scientific responsibilities of medical doctors may be taken on by clinical scientists, and medical doctors will instead be expected to perform a much more patient facing role. The exception in microbiology is the sub-discipline of virology, which is well suited to the expertise of clinical scientists due to reliance on cutting-edge scientific methods, increasing use of specialised genetic technologies, and a technical understanding of virus biology, with a reduced emphasis on patient management compared with microbiology as a whole.

=== Epidermal-dermal signaling === Silicone-related products can reduce the growth factor production of fibroblasts in hypertrophic scars and keloids. However, the relevance is unclear as silicone products do not have direct contact with dermal fibroblasts but with the epidermis only. Possible relevance may be due to the initiation of a signaling cascade by the epidermis. Through the signaling cascade, the epidermis regulates dermal fibroblast extracellular matrix production. Delayed epithelialization, which raises the risk of hypertrophic scar formation, is less likely to happen. A negative static electric charge is formed by friction between the silicone gel sheet and the skin. The charge induces collagen realignment, aiding the elimination of the scar. Moreover, the negative electric field leads to the polarization of scar tissues and thus scar shrinkage.

Sources: en.wikipedia.org

Reference notes

=== Superintelligence and the singularity === A superintelligence is a hypothetical agent that would possess intelligence far surpassing that of the brightest and most gifted human mind. If research into artificial general intelligence produced sufficiently intelligent software, it might be able to reprogram and improve itself. The improved software would be even better at improving itself, leading to what I. J. Good called an "intelligence explosion" and Vernor Vinge called a "singularity". In Artificial Intelligence: A Modern Approach, Russel and Norvig cast doubt on the possibility of a singularity, arguing that "so far, every technology has followed an S-shaped curve", and that "sometimes it is not possible to keep the growth going."

=== Background === Mogo is a sentient and living planet. When it is desired, its affiliation with the Corps is shown with foliage arranged into a green band, marked with the standard Green Lantern Corps lantern symbol, circling Mogo's equator. In its early appearances, Mogo is not a social Green Lantern and its interactions with the rest of the DC universe are not well documented. It avoids announcing its presence, preferring to represent itself using pseudonymous holograms. In Mogo's first appearance, it is explained that the planet-sized Mogo's gravitational field would wreak havoc on any other planet it would try to "visit", hence Mogo "doesn't socialize". At the same time, Mogo has allowed alien races to live on its surface and has been willing to change its conditions to suit them. When Parallax, possessing Hal Jordan, destroys the power battery on Oa and kills the Guardians, Mogo loses contact with the Green Lantern energy that helped sustain him. Without energy, Mogo loses consciousness and drifts through Sector 1014 until he is discovered by a nomadic alien race, who strip Mogo of his natural resources and pollute his environment. Mogo's body reacts instinctively, creating constructs to hinder the aliens' efforts to exploit his resources. Mogo is finally rescued by Kyle Rayner, who uses his power ring to reawaken him. With the restoration of the Green Lantern Corps, Mogo has taken on the role of a training and recreation planet for his fellow Green Lanterns. Soranik Natu, Kyle Rayner, and other Lanterns have traveled to his sector to ask for his counsel.

== Applications == In the presence of iron chloride or copper chloride catalyst, or of liquid sulfur at 120 °C Diallyl disulfide can be used as a precursor for the synthesis of higher diallyl polysulfides (polysulfanes). In agriculture, diallyl disulfide and related diallyl polysulfides show useful activity as environmentally-benign nematicides. Diallyl disulfide is also a starting material for the synthesis of allicin. In the food industry, diallyl disulfide is used to improve the taste of meat, vegetables and fruits.

Sources: en.wikipedia.org

Notes from published material

== Further reading == Reineccius, Gary (1998). Sourcebook of Flavors. Berlin: Springer. ISBN 978-0-8342-1307-4. Fennema, O.R., ed. (1985). Food Chemistry (2nd ed.). New York: Marcell Dekker, Inc. pp. 46–50. Bell, L.N.; Labuza, T.P. (2000). Practical Aspects of Moisture Sorption Isotherm Measurement and Use (2nd ed.). Egan, MN: AACC Egan Press.

Also in October 2020, Lilly announced that the National Institutes of Health (NIH) ACTIV-3 clinical trial evaluating its monoclonal antibody, bamlanivimab (LYCoV555), found that bamlanivimab was not effective in treating people hospitalized with COVID-19, but data showed bamlanivimab might be effective in treating COVID-19 by reducing viral load, symptoms, and the risk of hospitalization in outpatients. Other studies, including the NIH ACTIV-2 trial and its own BLAZE-1 trial, continued to evaluate bamlanivimab. In November 2020, the FDA issued an emergency use authorization (EUA) for the investigational monoclonal antibody therapy bamlanivimab for the treatment of mild-to-moderate COVID-19 in adult and pediatric patients. In December 2020, Lilly announced it would acquire Prevail Therapeutics Inc. for $1 billion, boosting its pipeline in neurodegenerative disease gene therapies. In April 2021, the FDA revoked the emergency use authorization (EUA) that allowed and signaled FDA agreement for the investigational monoclonal antibody therapy bamlanivimab, when administered alone, to be used for the treatment of mild-to-moderate COVID-19 in adults and certain pediatric patients. On 18 May 2021, the FDA accepted Lilly's application for Tyvyt (sintilimab), in combination with Lilly's own Alimta (pemetrexed) and platinum chemotherapy for newly diagnosed nonsquamous non-small cell lung cancer. In July 2021, the company announced it would acquire Protomer Technologies for more than $1 billion.

This mating can cause bi-daily surges of prolactin which would normally occur in rodent pregnancy. Prolactin surges initiate the secretion of progesterone which maintains pregnancy and hence can initiate pseudopregnancy. The false maintenance of pregnancy exhibits the outward physical symptoms of pregnancy, in the absence of a foetus. Prolactin receptor activation is essential for normal mammary gland development during puberty in mice. Adult virgin female prolactin receptor knockout mice have much smaller and less developed mammary glands than their wild-type counterparts. Prolactin and prolactin receptor signaling are also essential for maturation of the mammary glands during pregnancy in mice.

Regardless of their usage, these substances gained popularity and began to be documented, information being passed down generations. There are Hindu poems dated back to around 2000 to 1000 BCE that spoke of performance enhancers, ingredients, and usage tips. Chinese texts date back to 2697 to 2595 BC. Roman and Chinese cultures documented their belief in aphrodisiac qualities in animal genitalia, while Egyptians wrote tips for treating erectile dysfunction. In post-classical West Africa, a volume titled Advising Men on Sexual Engagement with Their Women from the Timbuktu Manuscripts acted as a guide on aphrodisiacs and infertility remedies. It offered advice to men on "winning back" their wives. According to Hammer, "At a time when women’s sexuality was barely acknowledged in the West, the manuscript, a kind of Baedeker to orgasm, offered tips for maximizing sexual pleasure on both sides." Ambergris, yohimbine, horny goat weed, ginseng, alcohol, toads from the genus Bufo, and certain foods are recorded throughout these texts as possessing aphrodisiac qualities. While many plants, extracts, or manufactured hormones have been proposed as aphrodisiacs, there is little high-quality clinical evidence of their efficacy or long-term safety. In 2020, Brian Earp and Julian Savulescu published a philosophy book titled Love Drugs: The Chemical Future of Relationships (UK title Love Is the Drug: The Chemical Future of Our Relationships).

Sources: en.wikipedia.org

Frequently asked questions

What is TB-500 made of?

Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.

Is TB-500 the same as thymosin beta-4?

No. Thymosin beta-4 is a protein of 43 amino acids, while TB-500 is described as a short fragment of it. The two differ in size, structure, and the range of interactions each can support.

Why do product descriptions differ between suppliers?

Naming for research peptides is not centrally coordinated, so vendors set their own labels and specifications. Differences in stated sequence, molecular weight, or purity documentation usually trace back to those independent labeling choices.

Is TB-500 the same as thymosin beta-4?

No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.

Network